Showing results (31-40 of 55) with videos related to
Sort By:
Pageof 6
Journal of Medicinal Chemistry|February 20, 2018
Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray StructuresJohn A Christopher, Zoltán Orgován, Miles Congreve, et al.Computer Methods and Programs in Biomedicine|March 4, 2017
Biopharmaceutics data management system for anonymised data sharing and curation: First application with orbito IMI projectKristin Lacy-Jones, Philip Hayward, Steve Andrews, et al.Journal of Medicinal Chemistry|July 31, 2015
Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)John A Christopher, Sarah J Aves, Kirstie A Bennett, et al.Alzheimer'S Research & Therapy|April 22, 2021
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose studyCharlotte Bakker, Tim Tasker, Jan Liptrot, et al.British Journal of Clinical Pharmacology|April 23, 2021
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1 -acetylcholine receptor agonist: A randomized cross-over trialCharlotte Bakker, Samantha Prins, Jan Liptrot, et al.Angewandte Chemie (International Ed. in English)|June 17, 2020
X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A2A Adenosine Receptor AntagonistsWillem Jespers, Grégory Verdon, Jhonny Azuaje, et al.Alzheimer'S & Dementia (New York, N. Y.)|March 1, 2022
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's diseasePradeep J Nathan, S Babli Millais, Alex Godwood, et al.British Journal of Clinical Pharmacology|December 22, 2020
First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1 -receptor partial agonist for the treatment of dementiasCharlotte Bakker, Tim Tasker, Jan Liptrot, et al.Nature|June 1, 2017
Crystal structure of the GLP-1 receptor bound to a peptide agonistAli Jazayeri, Mathieu Rappas, Alastair J H Brown, et al.Nature|July 13, 2017
Corrigendum: Crystal structure of the GLP-1 receptor bound to a peptide agonistAli Jazayeri, Mathieu Rappas, Alastair J H Brown, et al.Pageof 6